华福证券认为，港股创新药（含Pharma）为医药板块中最强势的板块，其次为创新药产业链CRO板 块，创新药已成为市场认可的主线之一，个股方面从主流一二线标的，行情亦在向有创新药布局或BD 预期的中药或仿制药标的扩展。短期创新药建议积极拥抱龙头和一线标的。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 消息面上，据央视新闻，6月13日国务院常务会议召开研究优化药品和耗材集采有关举措。会议指出， 要加强药品和耗材集采政策评估，总结经验、补齐短板，推动集采工作规范化制度化常态化开展。要更 好促进"三医"协同发展和治理，完善公立医院补偿机制，支持医药企业提高创新能力，更好满足群众多 元化就医用药需求。要加强对药品和耗材生产、流通、使用全链条质量监管，扎实推进仿制药质量和疗 效一致性评价，让人民群众用药放心安心。 东吴证券指出，创新药BD推动及优秀临床数据下，看好的医药子行业排序分别为：创新药>CXO>中药 >医疗器械>药店>医药商业等。具体标的选择思路：从成长性角度选股，主要集中创新药领域；从左侧 角度选股，主要集中在CXO、医疗器械。 6月16日，创新药概念小幅 ...

Core Viewpoint - Kexing Pharmaceutical (688136.SH) plans to sell its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., for 15 million yuan to reduce management costs and improve asset operation efficiency [1][13]. Group 1: Company Performance - Kexing Pharmaceutical's stock price has doubled since the beginning of the year, with a significant increase of 156.50% from 21.86 yuan per share at the end of 2024 to 56.07 yuan on June 4 [6][10]. - The company reported a revenue of 14.07 billion yuan in 2024, an increase of 11.75% year-on-year, and achieved a net profit of 31 million yuan, marking a turnaround from previous losses [10][11]. - Despite the revenue growth, the company's R&D expenses significantly decreased to 168 million yuan in 2024, down 51.30% from the previous year [11][13]. Group 2: Shareholder Actions - The controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., plans to reduce its stake by up to 3%, potentially cashing out over 336 million yuan based on the stock price at the time of the announcement [4][5]. - This is the first time since Kexing Pharmaceutical's IPO that the major shareholder has announced a reduction in holdings, raising market concerns about the intention behind the move [3][5]. Group 3: Market Reactions - Following the announcement of the major shareholder's reduction plan, Kexing Pharmaceutical's stock price fell to 50.95 yuan per share by June 12 [8]. - Market skepticism arose due to the significant stock price increase prior to the reduction announcement, with some investors questioning the motives behind the shareholder's decision [5][6].

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

Group 1 - Kexing Pharmaceutical plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tong'an Pharmaceutical Co., Ltd. for 15 million yuan, as the subsidiary has not conducted business in recent years and holds 20 drug approval numbers [1] - The sale aligns with Kexing's strategy to focus on the biopharmaceutical sector, enhancing core competitiveness and reducing operational risks, which is expected to increase profit and cash flow in 2025 [1] Group 2 - Renfu Pharmaceutical announced the resignation of three executives, including the president and vice president, due to personal reasons, which may raise concerns about management stability and strategic execution in the short term [2] - The new president, Du Wentao, is an internal candidate with extensive experience, which may facilitate a smooth transition [2] Group 3 - Lianhuan Pharmaceutical was fined approximately 61.04 million yuan for violating antitrust laws by engaging in a price-fixing agreement with competitors regarding a raw material [3] - The penalty includes the confiscation of illegal gains and a fine, which may impact the company's operational stability and profitability, potentially leading to short-term stock price pressure [3] Group 4 - ST Jingfeng is involved in a significant lawsuit concerning a contractual liability dispute with an amount of 76.98 million yuan at stake, with the court having accepted the case [4] - The lawsuit's outcome remains uncertain, which may affect investor confidence and lead to stock price volatility [4] Group 5 - Zhongsheng Pharmaceutical reported abnormal stock trading fluctuations, with a cumulative price deviation exceeding 20% over two trading days [5][6] - The company is conducting Phase III clinical trials for its product RAY1225, but the progress remains uncertain, raising concerns about the sustainability of the high stock price [6]

Meeting Overview - The second meeting of the second supervisory board of the company was held on June 9, 2025, with all three supervisors present [2][3]. Resolution Summary - The supervisory board approved the proposal to transfer 100% equity of its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., to Guangxi Drug Research Institute Co., Ltd. for a price of 15 million yuan [4][10]. - The board concluded that the transaction would enhance asset operation efficiency and is in line with the company's actual situation, with no harm to shareholders' interests [4][10]. Transaction Details - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and there are no significant legal obstacles to its implementation [8][10]. - The transfer price of 15 million yuan was agreed upon based on voluntary and fair negotiations [14]. Subsidiary Overview - Shenzhen Tong'an Pharmaceutical has not conducted actual business in recent years and primarily holds approval numbers for 20 pharmaceutical products [13]. - The subsidiary's ownership is clear, with no encumbrances or legal issues affecting the transfer [13]. Financial Impact - The sale of the subsidiary is expected to increase the company's profit and cash flow in 2025, aligning with the company's strategic focus on the biopharmaceutical sector [21].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十一 次会议于 2025 年 6 月 9 日以现场的方式召开。会议通知已于 2025 年 6 月 6 日发 出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-034 科兴生物制药股份有限公司 第二届监事会第二十一次会议决议公告 科兴生物制药股份有限公司监事会 2025 年 6 月 11 日 （一）审议通过《关于转让全资子公司股权的议案》 公司监事会认为：考虑到公司全资子公司深圳同安医药有限公司（以下简称 "同安医药"）近年来未实际开展业务，将公司持有的同安医药 100%的股权作 价 1,500 万元转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研 所"），有助于提高资产运营效率，符合公司的实际情况。本次交易 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-035 科兴生物制药股份有限公司 关于转让全资子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）拟将持有 的全资子公司深圳同安医药有限公司（以下简称"同安医药"或"标的公司"）100% 的股权转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研所"）， 转让价格为1,500.00万元。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，且交易实施不存在重大法律障碍。 本次交易已经公司第二届董事会第二十五次会议审议通过，无需提交股 东大会审议。 一、交易概述 广西药研所由广西恒拓医药投资集团有限公司（以下简称"恒拓医药"）与南 宁高新工业企业发展投资基金中心（有限合伙）（以下简称"南宁高新基金"）共 同出资设立。恒拓医药是一家以药品研发、生产与销售为主的集团公司，2024 年收入规模达 5.34 亿元，总资产约 7.83 亿元；南宁 ...

Key Points - The core viewpoint of the articles highlights various corporate activities including project investments, sales data, stock acquisitions, share buybacks, and shareholding changes across multiple companies in different sectors. Company Activities - Co-creation Turf has a low proportion of domestic sports turf in its main business revenue [1] - Zhongcai Technology plans to invest in a manufacturing base for 110 sets of 100-meter wind turbine blades annually [1][2] - Huakang Clean has won a contract for the construction and equipment procurement of the first phase of the Chongqing 13th People's Hospital [1][2] - Jindi Group achieved a cumulative signed amount of 14.05 billion yuan from January to May [1][2] - Leidi Ke intends to acquire 51% of Yuzhan Precision, entering the embodied intelligence field [1][2] - Youfa Group has completed a share buyback, repurchasing 1.79% of its shares [1][3] - Jindun Co. plans to reduce its shareholding by up to 2% [1][3] - Caida Securities' shareholder Guokong Operations intends to reduce its stake by up to 3% [1][3] - Batong Energy plans to raise no more than 385 million yuan through a private placement to its controlling shareholder [1][3] - Founder Technology aims to raise no more than 1.98 billion yuan for an AI and high-density interconnect circuit board project [1][4]

Group 1 - Zhongtai Securities' controlling shareholder plans to increase its stake in the company by 300 million to 500 million yuan within three months, representing up to 0.76% of the total share capital [2] - Fangzheng Technology intends to raise no more than 1.98 billion yuan through a private placement, with the controlling shareholder participating in the subscription [4] - Kexing Pharmaceutical plans to transfer 100% equity of its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., to Guangxi Zhuang Autonomous Region Drug Research Institute, with no significant legal obstacles [2] Group 2 - Deep Kangjia A has decided to terminate the acquisition of 78% equity in Hongjing Microelectronics due to disagreements on core terms with the counterparty [6] - Haimer Technology is planning a change in company control, with stock suspension continuing for up to three trading days [7] - Dongfang Electric Heat has signed a strategic cooperation agreement with Shanghai Zhishi to develop electronic skin for robots [8] Group 3 - Redik plans to acquire 51% equity in Chengzhan Precision Technology Co., Ltd. for a total consideration of 104 million yuan, aiming to enter the embodied intelligence field [9] - Vanke A sold 22 million A-shares on June 10, raising approximately 146 million yuan, accounting for 0.18% of the total share capital [10] - Jintai Technology has not yet engaged in any business related to stablecoin concepts, despite recent market interest [11] Group 4 - Apac Co., Ltd. received a project designation from a large domestic automotive group, with an expected total sales amount of approximately 360 million yuan over a six-year lifecycle [12] - Ice Wheel Environment won two large cold chain projects with a total bid price exceeding 190 million yuan, representing about 2.9% of the company's projected revenue for 2024 [13] - Songyuan Safety received a project designation from a well-known domestic automotive manufacturer, totaling approximately 45 million yuan [14]